A Phase 3 clinical trial referencing lanreotide began recruiting, according to a status update dated September 16, 2026. The study, registered as NCT06878664, is titled "Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors."
The trial's current status is listed as recruiting. It is registered as a Phase 3 study on ClinicalTrials.gov under identifier NCT06878664.
No results have been posted for this trial at this time. The available data indicate only the trial's title, phase, and recruiting status as of the update date. This brief does not state or imply any outcomes, efficacy, or safety conclusions, since none have been reported for this study to date.
Readers interested in additional background can consult the lanreotide compound overview for further context.